Federal health advisers are recommending approval for a highly-anticipated cholesterol drug, but with the caveat that more data is needed about its long-term ability to reduce heart attacks. A panel of ...
FDA panel backs first-in-class cholesterol drug from Sanofi source: http://finance.yahoo.com/news/fda-panel-backs-first-class-212320571.html
0 commentaires:
Enregistrer un commentaire